Gilead Sciences, Inc. and Tubulis have entered into an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target.   Tubulis will receive $20 million upfront and, if Gilead exercises its option, a separate option exercise fee of $30 million. Tubulis will also be eligible for development and commercialization milestones totaling up to $415 million, plus royalties on sales of marketed products resulting from the collaboration. Tub...